PT2057125E - Inibidores n?o nucle?sidos de transcriptase inversa - Google Patents

Inibidores n?o nucle?sidos de transcriptase inversa Download PDF

Info

Publication number
PT2057125E
PT2057125E PT07802503T PT07802503T PT2057125E PT 2057125 E PT2057125 E PT 2057125E PT 07802503 T PT07802503 T PT 07802503T PT 07802503 T PT07802503 T PT 07802503T PT 2057125 E PT2057125 E PT 2057125E
Authority
PT
Portugal
Prior art keywords
reverse transcriptase
transcriptase inhibitors
nucleoside reverse
nucleoside
inhibitors
Prior art date
Application number
PT07802503T
Other languages
English (en)
Inventor
Wylie Solang Palmer
Joshua Kennedy-Smith
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT2057125E publication Critical patent/PT2057125E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT07802503T 2006-08-16 2007-08-06 Inibidores n?o nucle?sidos de transcriptase inversa PT2057125E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83827206P 2006-08-16 2006-08-16

Publications (1)

Publication Number Publication Date
PT2057125E true PT2057125E (pt) 2011-05-31

Family

ID=38663155

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07802503T PT2057125E (pt) 2006-08-16 2007-08-06 Inibidores n?o nucle?sidos de transcriptase inversa

Country Status (23)

Country Link
US (2) US7713974B2 (pt)
EP (1) EP2057125B1 (pt)
JP (1) JP5216768B2 (pt)
KR (1) KR101401811B1 (pt)
CN (1) CN101501002B (pt)
AR (1) AR062366A1 (pt)
AT (1) ATE503744T1 (pt)
AU (1) AU2007286345B2 (pt)
BR (1) BRPI0715193A2 (pt)
CA (1) CA2658984C (pt)
CL (1) CL2007002346A1 (pt)
DE (1) DE602007013573D1 (pt)
DK (1) DK2057125T3 (pt)
ES (1) ES2360893T3 (pt)
IL (1) IL196655A (pt)
MX (1) MX2009001198A (pt)
NO (1) NO20090405L (pt)
PE (1) PE20080734A1 (pt)
PL (1) PL2057125T3 (pt)
PT (1) PT2057125E (pt)
RU (1) RU2451676C2 (pt)
TW (1) TWI417293B (pt)
WO (1) WO2008019968A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
CN101679414A (zh) * 2007-04-09 2010-03-24 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
WO2009067597A1 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf 4- (or 5-) substituted catechol derivatives
MX2010006397A (es) * 2007-12-21 2010-07-05 Hoffmann La Roche Compuestos heterociclicos antivirales.
JP2012509342A (ja) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
WO2011143646A1 (en) * 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2012078416A2 (en) * 2010-12-06 2012-06-14 Rfs Pharma, Llc Monophosphate prodrugs of dapd and analogs thereof
US9487506B2 (en) * 2011-04-13 2016-11-08 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
RU2573975C2 (ru) 2011-04-26 2016-01-27 Дзе Проктер Энд Гэмбл Компани Абсорбирующие компоненты с повышенной объемностью
KR20140135843A (ko) 2012-04-25 2014-11-26 더 프록터 앤드 갬블 캄파니 웨브를 개구형성 및 신장시키기 위한 장치 및 공정
CA2871680C (en) 2012-04-25 2018-01-09 The Procter & Gamble Company Corrugated and apertured web
WO2014091265A1 (en) 2012-12-11 2014-06-19 Aurigene Discovery Technologies Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
JP6321965B2 (ja) 2014-01-09 2018-05-09 富士フイルム株式会社 有機薄膜トランジスタ、有機半導体薄膜および有機半導体材料
CN106614663A (zh) * 2016-12-29 2017-05-10 新沂市中诺新材料科技有限公司 一种新型纳米级吲唑类农药合成方法
CN113511960A (zh) * 2021-08-20 2021-10-19 郑州华赞医药科技有限公司 一种1-氯-3-甲氧基-5-甲基苯的合成方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4949314A (en) 1966-08-16 1990-08-14 The United States Of America As Represented By The Secretary Of The Navy Method and means for increasing echo-ranging-search rate
US3682932A (en) 1970-11-23 1972-08-08 Hoffmann La Roche 2-chloro-6-hydroxynicotinic acid
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4189718A (en) * 1978-03-02 1980-02-19 Carson Manufacturing Company, Inc. Electronic siren
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8327880D0 (en) 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
AU622926B2 (en) 1988-09-09 1992-04-30 Nippon Kayaku Kabushiki Kaisha Pyrimidine or purine cyclobutane derivatives
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5489697A (en) 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
BR9509024A (pt) 1994-09-26 1997-09-30 Shionogi & Co Derivados de imidazol
EP0809511A1 (en) 1995-02-16 1997-12-03 F. Hoffmann-La Roche Ag Inhibition of angiogenesis using interleukin-12
IL117574A0 (en) 1995-04-03 1996-07-23 Bristol Myers Squibb Co Processes for the preparation of cyclobutanone derivatives
WO2000016625A1 (en) 1998-09-23 2000-03-30 University Of Kentucky Research Foundation Antiviral drug compositions containing lithium inorganic salts
FR2783826B1 (fr) 1998-09-29 2002-07-19 Rhodia Chimie Sa Procede de preparation de 4-hydroxyquinoleines et/ou formes tautomeres
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
ATE299865T1 (de) 1999-05-04 2005-08-15 Schering Corp Piperazinderivate verwendbar als ccr5 antagonisten
CN1524527A (zh) 1999-05-04 2004-09-01 ���鹫˾ 用作ccr5拮抗剂的哌啶衍生物
PT1284974E (pt) 2000-05-26 2004-06-30 Pfizer Derivados de triazoliltropano como moduladores de ccr5
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
GB0024795D0 (en) * 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
US6620586B2 (en) 2001-02-20 2003-09-16 Applied Gene Technologies, Inc. Methods and compositions for analyzing nucleic acids
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
GB0108046D0 (en) 2001-03-30 2001-05-23 Astrazeneca Ab Chemical compounds
ME00558A (en) 2001-04-10 2011-12-20 Pyrazole derivatives for treating hiv
GB0113524D0 (en) 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives
GB0127547D0 (en) 2001-11-16 2002-01-09 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
JP2006504803A (ja) 2002-09-26 2006-02-09 ファイザー・インク ピラゾール誘導体
AU2003263455A1 (en) 2002-09-26 2004-04-19 Pfizer Inc. Pyrazole amides for treating hiv infections
GB0223234D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
AR042628A1 (es) 2002-12-20 2005-06-29 Astrazeneca Ab Derivados de piperidina como moduladores del receptor ccr5
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
BRPI0408704A (pt) 2003-03-24 2006-03-07 Hoffmann La Roche benzil-piridazinonas como inibidores de transcriptase reversa
US7220772B2 (en) * 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
WO2005075484A2 (en) 2004-02-10 2005-08-18 F. Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
WO2005090317A1 (en) * 2004-03-23 2005-09-29 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
US7625949B2 (en) * 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
CA2569910A1 (en) 2004-06-09 2005-12-22 Eun Kyung Lee Octahydro-pyrrolo[3,4-c] derivatives and their use as antiviral compounds
MX2007000788A (es) * 2004-07-27 2007-03-23 Hoffmann La Roche Compuestos de benciltriazolona como inhibidores no nucleosidos de transcriptasa inversa.
CA2577144C (en) * 2004-09-30 2011-06-21 Boehringer Ingelheim International Gmbh Alkynyl compounds as non-nucleoside reverse transcriptase inhibitors
JP2008525419A (ja) 2004-12-22 2008-07-17 ファイザー・リミテッド Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤
CN101180280A (zh) * 2005-03-24 2008-05-14 弗·哈夫曼-拉罗切有限公司 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
ES2317584T3 (es) * 2005-09-30 2009-04-16 F. Hoffmann-La Roche Ag Inhibidores de nnrt.
EP1940782B1 (en) * 2005-10-19 2009-03-11 F.Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inhibitors
BRPI0617720A2 (pt) * 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
JP2009529047A (ja) * 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環系ピラゾール化合物およびその使用
MX2009009793A (es) * 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
EP2408772B1 (en) * 2009-03-19 2015-07-01 Medical Research Council Technology Compounds

Also Published As

Publication number Publication date
RU2451676C2 (ru) 2012-05-27
ATE503744T1 (de) 2011-04-15
KR101401811B1 (ko) 2014-05-29
NO20090405L (no) 2009-01-30
WO2008019968A1 (en) 2008-02-21
US20080045511A1 (en) 2008-02-21
JP2010500392A (ja) 2010-01-07
PE20080734A1 (es) 2008-06-14
US8063064B2 (en) 2011-11-22
US20110059975A1 (en) 2011-03-10
US7713974B2 (en) 2010-05-11
CL2007002346A1 (es) 2008-03-14
CA2658984A1 (en) 2008-02-21
AR062366A1 (es) 2008-11-05
AU2007286345B2 (en) 2012-03-08
MX2009001198A (es) 2009-02-11
KR20090040438A (ko) 2009-04-24
AU2007286345A1 (en) 2008-02-21
RU2009109354A (ru) 2010-09-27
DK2057125T3 (da) 2011-05-16
IL196655A0 (en) 2009-11-18
DE602007013573D1 (de) 2011-05-12
CN101501002B (zh) 2012-06-27
CA2658984C (en) 2014-12-02
PL2057125T3 (pl) 2011-09-30
JP5216768B2 (ja) 2013-06-19
CN101501002A (zh) 2009-08-05
EP2057125A1 (en) 2009-05-13
IL196655A (en) 2012-09-24
ES2360893T3 (es) 2011-06-10
TW200817397A (en) 2008-04-16
EP2057125B1 (en) 2011-03-30
TWI417293B (zh) 2013-12-01
BRPI0715193A2 (pt) 2013-10-01

Similar Documents

Publication Publication Date Title
ZA200903395B (en) Non-nucleoside reverse transcriptase inhibitors
IL196655A0 (en) Non-nucleoside reverse transcriptase inhibitors
EP2076492A4 (en) NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
EP2217069A4 (en) INHIBITORS OF NON-NUCLEOSIDE INHIBITORS OF THE REVERSE TRANSCRIPTASE
IL205386A0 (en) Non - nucleoside reverse transcriptase inhibitors
IL200748A0 (en) Non-nucleoside reverse transcriptse inhibitors
AP2514A (en) HIV reverse transcriptase inhibitors
TWI372619B (en) Non-nucleoside reverse transcriptase inhibitors
EP2220091A4 (en) REVERSE transcriptase inhibitors
ZA201000023B (en) Novel hiv reverse transcriptase inhibitors
ZA200803174B (en) N-phenyl phenylacetamide non-nucleoside reverse transcriptase inhibitors
IL188615A0 (en) Hiv reverse transcriptase inhibitors
PT2402319T (pt) Inibidores de dgat
ZA200901073B (en) Kinase inhibitor
DK2383271T3 (da) Aminoquinoloner som GSK-3-inhibitorer
IL180495A0 (en) Benzyltriazolone compounds as nin-nucleoside reverse transcriptase inhibitors
IL194494A0 (en) Thiazolyldihydrocyclopentapyrazoles for use as pi3-kinase inhibitors
IL200886A0 (en) Non-nucleoside reverse transcriptase inhibitors
ZA200900071B (en) Non-nucleoside reverse transcriptase inhibitors
EP2177529A4 (en) NEW DE-SECRETASE INHIBITOR
EP1899340A4 (en) NON-NUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS
IL202143A0 (en) Non-nucleoside reverse transcriptase inhibitors
EP2222662A4 (en) INHIBITORS OF KYNURENINE AMINO TRANSFERASE
ZA200800185B (en) Hiv reverse transcriptase inhibitors
IL197981A0 (en) Kinase inhibitors